SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- obesity/erectile dysfunction

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche12/1/2016 5:25:43 PM
   of 435
 
Mol Pharmacol. 2016 Nov 28. pii: mol.116.104638. [Epub ahead of print]

Cannabinoid Receptor Interacting Protein (CRIP) 1a competition with ß-arrestin for CB1 receptor binding sites.

Blume LC1, Patten T2, Eldeeb K1, Leone-Kabler S1, Ilyasov AA1, Keegan BM1, O'Neal JE1, Bass CE1, Hantgan RR1, Lowther WT1, Selley DE3, Howlett AC4.

1Wake Forest School of Medicine.
2Wake Forest University.
3Virginia Commonwealth University.
4Wake Forest School of Medicine; ahowlett@wakehealth.edu.

Cannabinoid Receptor Interacting Protein1a (CRIP1a) is a CB1 receptor (CB1R) distal C-terminus-associated protein that alters CB1R interactions with G-proteins (Blume et al.,2015; Smith et al.,2015). We tested the hypothesis that CRIP1a is capable of also altering CB1R interactions with ß-arrestin proteins that interact with the CB1R at the C-terminal. Co-immunoprecipitation studies indicated that CB1R associates in complexes with either CRIP1a or ß-arrestin, but CRIP1a and ß-arrestin fail to co-immunoprecipitate with each other. This suggests a competition for CRIP1a and ß-arrestin binding to the CB1R, which we hypothesized could attenuate the action of ß-arrestin to mediate CB1R internalization. We determined that agonist-mediated reduction of the density of cell surface endogenously-expressed CB1Rs was clathrin- and dynamin-dependent, and could be modeled as agonist-induced aggregation of transiently-expressed GFP-CB1R. CRIP1a over-expression attenuated CP55940-mediated GFP-CB1R as well as endogenous ß-arrestin redistribution to punctae, and conversely, CRIP1a knock-down augmented ß-arrestin redistribution to punctae. Peptides mimicking the CB1R C-terminus could bind to both CRIP1a in cell extracts as well as purified recombinant CRIP1a. Affinity pull-down studies revealed that phosphorylation at threonine-468 of a CB1R distal C-terminus 14-mer peptide reduced CB1R-CRIP1a association. Co-immunoprecipitation of CB1R protein complexes demonstrated that central or distal C-terminal peptides competed for the CB1R association with CRIP1a, but that a phosphorylated central C-terminal peptide competed for association with ß-arrestin1, and phosphorylated central or distal C-terminal peptides competed for association with ß-arrestin2. Thus, CRIP1a can compete with ß-arrestins for interaction with C-terminal CB1R domains which could affect agonist-driven, ß-arrestin-mediated internalization of the CB1R.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext